drugset / Trial / NCT04081714
Intermediate Expanded Access Protocol CNMAu8.EAP03
Expanded access
Temporarily not available
Clene Nanomedicine
University of Texas, Southwestern Medical Center at Dallas · collab
Summary
This is a single-center intermediate expanded access program to provide access to the investigational product, CNM-Au8, up to 25 participants diagnosed with Multiple Sclerosis.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNM-Au8 | Other / unclassified | 30 mg | Oral |